Spouses, survivors don't see eye to eye after bone marrow transplants

In a newly published study, researchers interviewed thirty spouse–survivor pairs (averaging 13 years post-BMT) looking to identify "lasting life changes." Specifically, they were asked to identify:

- Their most significant long-lasting change since cancer/BMT
- Their most significant positive change
- Their most significant negative change
- Whether the experience had affected them and their spouse differently

Spouses more often reported negative changes (24%) than survivors (15%), and survivors more often reported positive changes (85%) than spouses (76%).

Both survivors and spouses said the most significant positve change was in their ‘perspective/outlook on life’, and that the most significant negative change was ‘lingering health effects' (although survivors mentioned this twice as often).

Interestingly, spouses "were more likely to talk about changes in the first-person plural (we, us) that were largely emotional or in relation to the survivor, whereas survivors spoke of changes in the first-person singular (I, me) that occurred to them directly and were largely physical."

CONCLUSIONS
"Although both spouses and survivors described similar negative and positive long-lasting changes that continued an average of 13 years post-BMT, they reported differences in the ways they were impacted by the experience, which was reflected in the language they used."

CANCER TYPE(S)
Not indicated

TREATMENT TYPE(S)
Bone marrow transplantation

WHERE WAS THIS RESEARCH PUBLISHED?
The journal Psycho-Oncology

By Ross Bonander

Citation
Bishop MM et al. "Comparison of lasting life changes after cancer and BMT: perspectives of long-term survivors and spouses." Psycho-Oncology. Published online: 4 AUG 2010, DOI10.1002/pon.1812

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap